Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Epigenetic therapy in hematological cancers

    Research output: Contribution to journalReviewResearchpeer-review

  2. Mycobacterium brisbanense lung infection facilitated by steroid induced adrenal insufficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The inflamed sputum in lower respiratory tract infection: l-lactate levels are correlated to neutrophil accumulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comparison of methods for measuring antibiotic consumption in an intensive care unit

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The importance of early diagnosis of Mycobacterium abscessus complex in patients with cystic fibrosis

    Research output: Contribution to journalReviewResearchpeer-review

  1. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Cascade Guideline

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Chronic Pancreatitis Is Characterized by Distinct Complication Clusters That Associate With Etiological Risk Factors

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

Original languageEnglish
JournalAPMIS - Journal of Pathology, Microbiology and Immunology
Volume127
Issue number1
Pages (from-to)27-32
Number of pages6
ISSN0903-4641
DOIs
Publication statusPublished - Jan 2019

    Research areas

  • Gastrointestinal pathology, IPMN subtyping, MUC1, pancreas cancer, pathology of tumors, prognostic markers

ID: 55881671